about
MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemiaIdentification of novel sequence variations in microRNAs in chronic lymphocytic leukemiaChromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data.Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsFunctional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.High-quality full-length immunoglobulin profiling with unique molecular barcoding.Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic LeukemiaWhole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsEpigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expressionDifferent spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clonesTowards error-free profiling of immune repertoires.Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.Analysis of prognostic significance of merkel cell polyomavirus in chronic lymphocytic leukemia.Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference.Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.[Chromosome banding analysis of peripheral blood lymphocytes stimulated with IL2 and CpG oligonucleotide DSP30 in patients with chronic lymphocytic leukemia].Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells.Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis.Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia.No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.Post-translational modifications regulate signalling by Ror1.COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration.The frequency ofTP53gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptorsTailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemiaCytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactBioinformatic pipelines for whole transcriptome sequencing data exploitation in leukemia patients with complex structural variants.Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemiaSingle cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients
P50
Q28257169-5DD132C2-4DB6-4B61-9F10-F4275D2D385CQ28303339-BAFA38CC-F283-498B-A190-F0F89623115CQ30685440-C2F83475-2565-4331-A590-7CDC272B488CQ35029461-E10E21E9-06BD-468B-A154-7A2A4F7AA8F0Q35671227-175B6A8B-881C-4C74-AB63-4ACF7AAA6C2DQ36094995-5B18C87F-9A60-4FDC-9A75-0F2C6AB6D82FQ36471596-969F29F4-46C2-4B39-8327-1864054D70E2Q36622188-6594215A-7FA4-4313-B705-FD3BFDBA2B2AQ36956957-C3172CED-51F2-4397-AA0D-92051A30BAE0Q37140491-B841370B-671F-4F36-99CA-34D6E6DB53B8Q37552043-7FCFC9A5-4F9C-40C6-BBFA-3B20ADA212A7Q38431084-B0FCF602-E0AC-4C8C-8F0A-C258F7BF10F1Q38744622-4ECC1B1F-2F49-411F-A2D8-358B8FFBDD0FQ39070644-F62E1A73-1D80-4733-9F50-92DA8363FD0EQ39876261-8B2F75A5-3E1A-4A85-B779-F093842678D8Q40188830-6C09DD5F-7168-4571-AEF2-6F02AD041BC3Q40455172-5150FAAA-A2A2-472E-8B38-484C6937CBE2Q41439388-68528529-91D5-4E07-BB6C-BD4D71F7A099Q41507971-3BFA83E8-9A49-42B6-84EE-AD3A6FD934AAQ42384352-592C8C78-8DBA-473E-BE93-AE8A5DEE469FQ42399823-5D6D986A-DAC1-49FA-94A0-DDC52FF599E1Q44895447-CAD8B89F-F3A5-4CF8-95BA-4BC395E0D9BBQ45346108-F489FFFE-A095-4357-A269-E201A4414B7CQ45874243-C448DE23-5341-42D6-BFF1-874D7A0AA1FDQ45880689-B55F7860-5D3B-49A8-B624-D9B02D1380B2Q46916349-DF555CE5-450F-47E9-A2AB-D98ED3E6776AQ48141361-85A47567-49B6-4582-8039-B0FB6E07F404Q49472515-3DBE9A88-2364-4441-B893-FBF007CEA867Q49925419-2AF44D33-783C-46DF-AE86-13B19F4F4EABQ50113330-75718F66-05BF-43F4-8FC3-2979B8A6B6CEQ50134687-CAE2C363-C07A-4FD9-8B47-4161BC1CF59FQ51768578-CC357952-609C-4CCB-B53C-7151C1C37B2DQ53098391-1E72D819-DAD4-4438-9CFE-7523E0D1A28AQ54455172-3BC391AB-D887-44EC-ACB0-DFC659FB67C8Q58041543-E3C646DF-1C72-475A-AD34-5C3E87F1DA37Q61803940-916149FA-38AB-488B-B039-1BC749549D51Q64091853-482E6FB5-EABF-4DDB-881F-70C1A780554EQ64936250-4C0DB779-0091-4886-975E-763A7D71020DQ83292194-88555197-7B86-4BE2-96B9-505C8A902514Q88018511-AF32CFC9-18F7-4297-9105-0BEF30D5F6CE
P50
description
researcher, ORCID id # 0000-0002-6148-8877
@en
wetenschapper
@nl
name
Karla Plevová
@ast
Karla Plevová
@br
Karla Plevová
@co
Karla Plevová
@cs
Karla Plevová
@da
Karla Plevová
@de
Karla Plevová
@en
Karla Plevová
@es
Karla Plevová
@fr
Karla Plevová
@id
type
label
Karla Plevová
@ast
Karla Plevová
@br
Karla Plevová
@co
Karla Plevová
@cs
Karla Plevová
@da
Karla Plevová
@de
Karla Plevová
@en
Karla Plevová
@es
Karla Plevová
@fr
Karla Plevová
@id
prefLabel
Karla Plevová
@ast
Karla Plevová
@br
Karla Plevová
@co
Karla Plevová
@cs
Karla Plevová
@da
Karla Plevová
@de
Karla Plevová
@en
Karla Plevová
@es
Karla Plevová
@fr
Karla Plevová
@id
P106
P1153
26027062200
36145332700
P21
P31
P496
0000-0002-6148-8877